Ricardo Serrano, MD
Adult Medicine · Merritt Island, FLNPI 1629180351
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Johnson & Johnson at 34.4% of the total. Reporting peaked in 2019 at $5,202 and has fallen 69.6% since, to $1,582 in 2025. Among adult medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $45.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- AstraZeneca$4K
- Novo Nordisk$2K
- GSK$1K
- Amgen$1K
- Lilly USA, LLC$1K
- plus $4K from 22 others
What the payments were for
- Food & beverage$19,32199%
- Education$2191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 113 | $6,718 |
| AstraZeneca | 53 | $3,737 |
| Novo Nordisk | 54 | $1,833 |
| GSK | 17 | $1,136 |
| Amgen | 17 | $1,053 |
| Lilly USA, LLC | 36 | $1,015 |
| Radius Health, Inc. | 8 | $598 |
| Merck | 27 | $578 |
| Boehringer Ingelheim | 27 | $471 |
| Bayer | 8 | $266 |
| Kowa Pharmaceuticals America, Inc. | 12 | $258 |
| Exact Sciences | 9 | $214 |
| Sanofi-aventis U.S. LLC | 12 | $210 |
| Pfizer | 9 | $209 |
| Daiichi Sankyo Inc. | 2 | $206 |
| Abbott | 3 | $198 |
| Amarin Pharma, Inc. | 5 | $153 |
| Novartis | 3 | $129 |
| Phathom Pharmaceuticals, Inc. | 1 | $126 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Stryker | 1 | $100 |
| Azurity Pharmaceuticals, Inc. | 3 | $68 |
| Biogen | 2 | $34 |
| Genentech USA, Inc. | 2 | $27 |
| Photonicare Inc | 1 | $27 |
| Almatica Pharma LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,540 in reported general payments places this provider in the 95th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 26 | $54,342 |
| JardianceEmpagliflozin | 41 | $46,113 |
| OzempicSemaglutide | 27 | $36,876 |
| EliquisApixaban | 26 | $32,201 |
| XareltoRivaroxaban | 31 | $31,672 |
| MounjaroTirzepatide | 19 | $25,343 |
| JanuviaSitagliptin Phosphate | 16 | $25,295 |
| FarxigaDapagliflozin Propanediol | 28 | $23,035 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,017 |
| TradjentaLinagliptin | 16 | $10,688 |
| Bydureon BciseExenatide Microspheres | 12 | $9,988 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $8,085 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,286 |
| Dexlansoprazole DrDexlansoprazole | 14 | $6,243 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic, Levemir | $1,833 | $96,42565 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $471 | $64,88568 claims |
| PfizerEliquis | $209 | $32,20126 claims |
| Johnson & JohnsonXarelto | $6,718 | $31,67231 claims |
| Lilly USA, LLCMounjaro | $1,015 | $25,34319 claims |
| MerckJanuvia | $578 | $25,29516 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,136 | $24,27946 claims |
| AstraZenecaFarxiga | $3,737 | $23,03528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Merritt Island
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Joshua RycusCoral Springs$13K
- Frederick WeigandDeltona$9K
- Hernando ChongMiami$9K
- Neri FranzonFt Lauderdale$9K
- Luis AlvarezBoca Raton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.